People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc | — | Biotechnology | Series C | $320.3M | $495.3M | 2022 |
| Liminal BioSciences Inc. | — | Biotechnology | Series B | $67.1M | $1.0B | 2020 |
Gary J. Bridger at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gary J. Bridger on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Michael Ross | 1 | 18 |
| Amy Schulman | 1 | 11 |
| Terrance McGuire | 1 | 9 |
| CARL L. GORDON | 1 | 7 |
| Michael Gray | 1 | 6 |
| Tillman U. Gerngross | 1 | 5 |
| Errik B. Anderson | 1 | 5 |
| Michael Wyzga | 1 | 5 |
| Tillman Gerngross | 1 | 5 |
| Claudio Nessi | 1 | 5 |
| William Aliski | 1 | 4 |
| Robert L. Birnbaum | 1 | 4 |
| Daniel Burgess | 1 | 4 |
| Paula Ragan | 1 | 3 |
| Michael L. Ross | 1 | 3 |
| Alison Lawton | 1 | 3 |
| Terrance L. McGuire | 1 | 3 |
| Adam Mostafa | 1 | 3 |
| Carl B Gordon | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.